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POPULAR SCIENCE SUMMARY OF THE THESIS 
 
The discovery of antibiotics not even a century ago was a sensation, that revolutionized the 
treatment of infectious diseases. Antibiotics exploit differences in the bacterial and human cells 
to specifically target structures in the bacterial intruders and selectively kill them without 
harming the human body. Unfortunately, the remarkable adaptation capabilities of bacteria to 
adverse conditions such as toxic chemicals came to play against our chemical defense 
strategies. Bacteria developed resistance to antibiotics, which endangers the effectivity of this 
treatment strategy. A loss of antibiotics as tools to treat bacterial infections poses a threat to the 
individual health and society in many ways. Therefore, we need new chemicals and innovative 
strategies to protect this valuable resource.  
Work comprising this thesis aimed for the discovery of chemicals, that kill bacteria. The human 
respiratory tract pathogen Streptococcus pneumoniae served as model organism. Two 
molecules were characterized and evidence for their mechanism of action is provided. By 
employing medicinal chemistry, biochemical analyses and microbiological characterizations, 
we found, that they inhibit the synthesis of the bacterial cell envelope. The compounds 
constitute chemical scaffolds, that provide a starting point for further research to improve their 
characteristics. Our investigations also gave insight and raised further questions about 
metabolic processes in the bacteria. The compounds described in this thesis could be tools for 
further research on new antibiotics.  
Sepsis is an acute bacterial blood infection and a life-threatening disease. The patient’s life 
depends on the prompt administration of an antibiotic, which requires fast diagnostics. We have 
worked on a method with the aim to isolate bacteria from blood. First, we developed a protocol 
that lysed only blood cells while not harming bacteria. Then, we employed a microfluidic 
technique, which isolated the bacteria from the remaining particles of the blood lysate with the 
help of acoustic waves. We envision, that this sample preparation method could be of help for 
the acceleration of sepsis diagnosis.  
In conclusion, the thesis hopes to contribute work serving research that aims to assure 
successful treatment of bacterial infections.  
  
ABSTRACT 
Evolving antibiotic resistance warrants the development of new therapeutic and diagnostic 
approaches as part of the strategies to secure future antibacterial therapies and preserve the 
compounds currently available. Work constituting the thesis characterized small molecules 
yielded from a screen for autolysis inducing compounds on Streptococcus pneumoniae. Two 
compound classes were characterized, and their targets identified.  
The alkylated di-cyclohexyl carboxylic acid 2CCA-1 was identified as a fatty acid mimetic, 
that is incorporated into pneumococcal phospholipids via the polyunsaturated host fatty acid 
metabolism pathway. The formed 2CCA-1 containing lipids alter membrane fluidity, and 
treatment with 3 µM 2CCA-1 resulted in decreased pneumococcal viability and cell wall 
hydrolase mediated lysis. Deletion of the fatty acid binding protein FakB3 rendered 
pneumococci resistant to 2CCA-1, which could explain the inherent 2CCA-1 resistance of 
Staphylococcus aureus as FakB3 homologues are predominantly absent in bacteria of the 
Bacillales order. The involvement of the transcriptional repressor of the endogenous fatty acid 
synthesis machinery FabT in 2CCA-1 resistance, showed that FakB3 dependent host fatty acid 
incorporation is regulated depending on extracellular fatty acid availability. 
The second compound class comprised analogs of 1-amino substituted Tetrahydrocarbazoles 
(THCz). THCz analogs are active in the low micromolar range against an array of gram-
positive bacteria as well as mycobacteria, Neisseria gonorrhoeae and Moraxella catarrhalis. 
Mode of action studies identified the pyrophosphate moiety of undecaprenyl pyrophosphate as 
the minimal binding motif for THCz, which depended on the central diamino moiety for 
activity. THCz analogs consequently inhibited cell wall, teichoic acid and capsular 
biosynthesis. Reduction of the polysaccharide capsule increased pneumococcal tolerance to the 
compound, but resistant mutants could not be obtained.  
Furthermore, we developed a microfluidic based sample preparation method for 
decomplexation of bacteria containing whole blood. First, blood cells were selectively lysed 
while preserving bacterial viability. For the reduction of the small, below micrometer sized 
debris, gradient acoustic focusing was developed, that allowed separation of bacteria from the 
blood lysate in a microfluidic channel. The so purified sample might facilitate further 
microfluidic downstream operations to accelerate antimicrobial susceptibility determination of 
the sepsis causing pathogen.  
In conclusion, the thesis work identifies the target of two new compounds with bactericidal 
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1.1 ANTIBIOTICS AND ANTIBIOTIC RESISTANCE 
Antibiotics are truly the magic bullets of modern medicine that Paul Ehrlich set out to discover 
(1, 2). The main classes of antibiotics currently used in the clinics are predominantly natural 
products derived from actinomycetes, bacteria or fungi (3) and selectively target prokaryotic 
but not eukaryotic cells.  
Resistance development is an inherent and ubiquitous consequence when bacteria are exposed 
to toxic chemicals (4) since they can adapt to adverse changes in their environment with 
incredible speed. This is on account of their short generation time that allows quick 
evolutionary adaptation by mutational changes as well as their efficient strategies for the 
exchange of genetic material by horizontal gene transfer even between different bacterial 
species (5, 6). 
Already when awarded with the Nobel Prize for the discovery of penicillin, Alexander Fleming 
warned that it is the under-dosage of bactericidal agents that provokes resistance development 
(7). Indeed, broad use and misuse of antibiotics tremendously speeded up the spread of 
resistance (8), and we have to deal with antibiotic resistant infections that were previously 
curable. This has been demonstrated by the spread of multi- and extended- antibiotic resistant 
bacteria especially in nosocomial infections, where even pan-drug resistant species have been 
identified (9-11).The World Health Organization (WHO) prioritized bacteria according to the 
importance for novel and innovative treatment regimes, emphasizing bacterial species in 
critical need for such, among them especially Acinetobacter baumanii, Pseudomonas 
aeruginosa and Enterobacteriacea (12). If no or insufficient countermeasures are taken to 
decelerate the current trend, antimicrobial resistance is predicted to cause 10 million deaths in 
2050, undoubtedly also because cornerstones of modern medicine such as cancer treatment and 
surgery are based on the use of antibiotics (13).  
The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) prioritizes six topics 
for global research campaigning against antimicrobial resistance (14) (Figure 1). Among them 
is the search for novel therapeutic approaches to treat bacterial infections, including the search 
for new antibacterial molecules and drug targets, the improvement of the pharmacological 
properties of existing and possibly neglected antibiotics or the identification of alternative 
approaches to treat bacterial infections (14). Furthermore, innovative and improved approaches 
for the diagnosis of bacterial infections and the pathogen`s antibiotic susceptibility 
determination are warranted (14).  
Two major strategies are applied for the discovery of novel antibacterial or antivirulence (15) 
molecules. Target based discovery approaches explore or specifically design chemicals for 
certain intellectually chosen targets, whereas phenotypic screens aim to discover chemicals that 
provoke a desired phenotype. The major classes of antibiotics were discovered empirically in 
the beginning of the antibiotic era (16). Not only have they revolutionized medical care, they 
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also served as probes to study bacterial physiology (17). The first example thereof is the 
discovery of metabolite accumulation in penicillin treated Staphylococcus aureus in 1949 (18), 
which laid the foundation for the identification of peptidoglycan precursors (17). Screening hits 
that evoke an aspired phenotype and bind to a certain molecular target might serve as research 
tools to understand the target’s biological role, explore or validate a drug target, and pave the 
way for drug development (19), provided they meet required characteristics of potency, 
selectivity and chemistry (20, 21).  
 
Figure 1 Research priority topics to combat antimicrobial resistance according to the Joint Programming Initiative on 
Antimicrobial Resistance (JPIAMR). In the JPIAMR agenda for strategical coordination of global antimicrobial resistance 
research, the public health threat is tackled from a one health perspective, considering human, animal and environmental aspects 
of antimicrobial use and resistance development (14). Priority topics comprise therapeutics, diagnostics and research on 
transmission dynamics, including the unravelling of the environment´s role thereto. Furthermore, innovative intervention 
strategies for infection prevention and improvements of surveillance strategies are pronounced topics indispensable to curb 
antimicrobial resistance. The graphic is reproduced with permission from JPIAMR (14). 
Innovations are needed for medical care of bacterial infections. None of the eight United States 
(US) Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved 
antibacterial agents since 2017, and only four out of 25 that are currently in pre-clinical 
development have a new mechanism of action (22). However, in current pre-clinical research 
and development, more than halve of the ongoing projects focus on non-conventional 
approaches to treat bacterial infections, such as antivirulence (33 projects), phage (33 projects), 
immune supportive (12 projects) or microbiota modulating (21 projects) therapies (23). 
Moreover, 131 currently ongoing projects explore small antibacterial molecules with a new 
target, and 56 focus on already established targets, which together constitute 46 % of the current 
preclinical antibacterial therapy research and development (23). 
1.2 STREPTOCOCCUS PNEUMONIAE 
Streptococcus pneumoniae is an extensively studied bacterial species, reflecting its role as a 
major human pathogen. Milestones in bacteriology, such as the development of the gram-stain, 
identification of natural genetic transformation and the first quorum sensing molecule as well 
as the discovery of the immunogenicity of capsular polysaccharide, have been set by studying 
S. pneumoniae (24, 25). It was also the first bacterium against which the first selectively acting 
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drug (optochin) was tested (25). S. pneumoniae moreover served as a model organism for the 
disclosure of deoxyribonucleic acid (DNA) as the carrier of genetic information (26), findings 
important beyond the research field of microbiology. Nevertheless, S. pneumoniae, which is 
commonly referred to as the pneumococcus, disguises many secrets, remains a widespread 
opportunistic pathogen and is one of the prioritized bugs for which novel antibiotics are needed 
(12). 
 
In this thesis, the pneumococcus is employed as a model organism for bactericidal hit discovery 
and mode of action studies.  
 Epidemiology, colonization and disease 
The discovery of S. pneumoniae took place already in the era during which the germ theory of 
disease was proven by Koch and Pasteur (27, 28). The first isolation of the pneumococcus in 
the laboratory from blood of rabbits that were subcutaneously infected with human saliva was 
reported by Sternberg and Pasteur in 1880 (28). The pneumococcus is a gram-positive 
organism comprising at least 98 serotypes with distinct polysaccharide capsules (29).  
Even though the first isolation of pneumococci was made from experimentally infected rabbits, 
and mice were subsequently found to display even higher susceptibility to pneumococcal 
infections (28), these were mainly consequences of the artificial test situations, which still serve 
valuably as animal models to study pneumococcal infectious disease (30). The pneumococcus 
is a human adapted pathogen and displays several virulence factors that might account for its 
host tropism. It expresses for instance a protease to selectively inactivate human 
immunoglobulin A (IgA), displays the pneumococcal surface protein C (PspC) to specifically 
interact with constituents of the human immune system such as factor H, and can 
discriminatively sense the human version of sialic acid in the mucus of the respiratory airways 
(31-33). Nonetheless, pneumococcal colonization is reported also in other mammals living in 
close contact with humans (34-36). 
S. pneumoniae commonly resides in the human nasopharynx as asymptomatic colonizer of up 
to 60 % of children and less than 10 % of the adult population (37), implying that worldwide 
around 1.9 - 5.8 billion people are colonized simultaneously (38). Transmission occurs via 
aerosol and droplets of nasal secretions through close person-to-person contact, as well as 
contact therewith from inanimate surfaces (29, 39, 40). In the majority of cases, pneumococcal 
colonization remains asymptomatic and of short duration (1-2 months), depending on the 
serotype and age of the host (41). The pneumococcus is adapted to a colonizing lifestyle and 
has evolved virulence strategies to successfully establish and maintain colonization as well as 
to promote transmission (Figure 2). Key determinants therefore are adherence strategies, 
subversion of the immune response, biofilm formation and the interaction with the residing 
microbiota. S. pneumoniae has to compete with other common colonizers of the 
nasopharyngeal niche, such as Haemophilus influencae, Moraxella catharralis or Neisseiria 
meningitidis (42, 43). The pneumococcus has the capacity for natural competence to acquire 
DNA from other pneumococcal strains that simultaneously colonize the nasopharynx or from 
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closely related Streptococci of the mitis group, such as Streptococcus mitis or Streptococcus 
pseudopneumoniae (44, 45). The resulting genome plasticity and vivid exchange of genetic 
material in the nasopharynx allow for the quick adaptation to environmental conditions, 
favoring persistence or transmission. 
 
Figure 2 Selected factors needed for the establishment of pneumococcal colonization. After entering a new host, S. 
pneumoniae encounters a thick (0,5 – 10 µm) viscoelastic mucous layer containing glyco-, immune- and other proteins, 
inorganic salts and lipids (38, 46, 47). The expression of a thick, negatively charged capsule enables the pneumococcus to repel 
the negatively charged mucous (29, 48). The expression of the cytotoxin pneumolysin (Ply), damages epithelial cells, which 
leads to a reduction in beating cilia (29) and affects clearance via the oral-fecal route (38, 46). Additionally, the mucus is 
degraded by sialidases such as neuraminidase NanA, thereby reducing clearance, facilitating access to the epithelium and 
simultaneously sequestering valuable carbon sources (33, 49, 50). After paving the way closer to the epithelium, adhesins such 
as the ancillary pilus subunit RrgA, (UniProtKB A7KT66) on the tip of pili, choline binding protein CbpA or the cell wall 
component phosphorylcholine (ChoP), anchor the pneumococcus to epithelial cells (29, 48). ChoP interacts with the platelet 
activating factor receptor (PAFR) (51). Capsule expression was observed to be reduced in close contact to epithelial cells, likely 
favoring adherence (52). Additionally, the pneumococcus possesses an armor of strategies to ward off the immune response. 
An example is the modification of the peptidoglycan with reduced acetylation, which increased resistance to lysozyme (53). 
The formation of a biofilm, a pneumococcal community embedded in an extracellular matrix, strengthens colonization as it 
increases tolerance to antibiotics and factors of the immune response, and facilitates horizontal gene transfer (54). 
S. pneumoniae can however spread from the nasopharynx to other, otherwise sterile tissues, 
and cause mild diseases like sinusitis and otitis media, but also severe invasive diseases such 
as pneumonia, sepsis, and meningitis (37). S. pneumoniae is the major causative pathogen of 
community acquired pneumonia (55-57). Sepsis can arise after pneumococcal invasion of the 
blood stream from the lungs in about one fourth of adult pneumonia cases (56), or in rare cases 
directly from the nasopharynx (occult bacteremia) (48). Colonization is a prerequisite for 
invasive disease but also for transmission, as pneumococcal pneumonia is not thought to be 
contagious (50, 58). Still, even though invasive disease is not the primary goal of pneumococcal 
evolution (38), S. pneumoniae is one of the most common causative bacterial agents of lower 
respiratory tract infections (LRTI) (59). LRTIs have been the 4th leading cause of death 
worldwide in 2010 (60), and remained the 8th leading cause of death in 2016 in high income 
countries (61). Pneumococcal LRTI claimed nearly 1.19 million deaths in 2016, among them 
341 029 deaths of children below the age of 5 (29 % of total fatal cases) and 494 340 deaths of 
individuals above the age of 70 (42 % of fatal cases) (62). 
The fate between colonization and invasive diseases relies on a finely tuned balance between 
pneumococcal virulence factors and the host immune system. Certain pneumococcal serotypes 
are more commonly isolated from colonized individuals, whereas others are associated with 
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invasive disease cases (37). Likewise, impairments of the immune system are known risk 
factors for the host to suffer from an invasive pneumococcal disease. Hence, young children 
with their immature immune system and individuals above the age of 65 with an aging immune 
system and comorbidities, constitute major risk groups (63). Furthermore, patients with 
immunosuppressive diseases (e.g. cancer, human immunodeficiency virus (HIV) infections), 
as well as individuals with underlying chronic malignancies (e.g. cardiovascular, chronic 
obstructive pulmonary diseases or diabetes mellitus), are at higher risk of invasive 
pneumococcal diseases (63, 64). Notably, a detrimental synergism of pneumococcal invasive 
diseases with viral co-infections of the influenza, rhino or respiratory syncytial viruses, is 
documented and accountable for disease severity (57, 65, 66). First observations for 
pneumococcal co-infections with the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in critically ill patients have also been reported (67). Furthermore, viral infections 
facilitate pneumococcal transmission through increased shedding as well as colonization 
susceptibility of the new host (29, 39, 68).  
Vaccines with different serotype coverage are available. The 23-valent pneumococcal 
polysaccharide vaccine (PPSV23) is recommended by the Centers for Disease Control and 
Prevention (CDC) for people above the age of 65 in the United States (US) and the 10- or 13-
valent pneumococcal conjugate vaccines (PCV10 or PCV13) have been introduced in the 
childhood vaccination program in many countries (69-72)  
 Antibiotic therapy and antibiotic resistance 
Standard treatment of S. pneumoniae relied mainly on β-lactam antibiotics such as penicillin 
(73). In the first roughly 20 years after the introduction of penicillin (1940s) (73), the 
pneumococcus was especially sensitive with a minimal inhibitory concentration (MIC) below 
0.06 µg / mL (74). In 1967 however, the first non - susceptible strains (MIC ≥ 0.12 µg/mL) 
were detected (74). The pneumococcus achieves β-lactam resistance primarily by altering the 
targeted enzymes as they are penicillin binding proteins (PBP) to reduce their penicillin binding 
affinity (73, 75). Resistance can additionally be achieved by mutations in multiple genes, for 
example the peptidoglycan bridge formation alanyltransferase murM (UniProtKB Q9L447), 
resulting in changes of the peptidoglycan composition (further described in chapter 2.1.2) (73, 
75-77). The overall extent of penicillin non-susceptibility in European pneumococcal invasive 
disease isolates from 2010 was reported to be 8.9 %, yet prevalently southern and eastern 
European countries bear penicillin resistance rates over 40 % (78). Their prevalence correlates 
with the antibiotic consumption (79, 80).  
Macrolides, targeting the ribosome to impair protein synthesis have been the choice of 
treatment for upper and lower respiratory tract infections when β - lactam resistance emerged 
(81). Unfortunately, with the consequence of widespread global macrolide resistance (81), with 
resistant isolates constituting 20 – 40 % of pneumococcal isolates in the US (82). Clindamycin, 
a licosamide, is also indicated for therapy of β - lactam resistant pneumococcal infections and 
remains effective towards 78 % of isolates tested in 2011 in the US, despite the danger of cross 
– resistance with macrolides (82). Similar sensitivities are observed in the US for the 
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bacteriostatic protein synthesis inhibiting tetracyclins and trimethoprim – sulfametoxazole that 
are stalling the essential pneumococcal folic acid synthesis (82). DNA gyrase inhibiting 
fluoroquinolones prevail, with an inherent moderate activity, effective towards S. pneumoniae, 
but resistance development is following an increasing trend (82). Vancomycin is a last resort 
antibiotic to treat pneumococcal infections, however since long vancomycin tolerant strains 
have been registered (74).  
Resistance is observed to expand due to the spread of successful clones. Their influence on 
antibiotic resistance infections is well-documented with the decline thereof in some areas after 
introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the childhood 
vaccination program, which includes highly penicillin resistant serotypes (83). 
1.3 SEPSIS AND SEPSIS DIAGNOSIS 
Generally, blood is regarded as a sterile body fluid free of microorganisms. Yet, through the 
emergence of culture-independent analytical methods, presence of a dormant microbiome has 
been described in several chronic diseases (84). Viable bacteria from the own human 
microbiome are frequently passing the lesioned epithelial barrier resulting from daily activities 
such as tooth hygiene (85). These bacteria are usually defeated immediately by the host’s 
immune system right at their entry side without noticeable symptoms (85, 86). When the fine 
balance between invading pathogen and the immune system is perturbed, a systemic 
inflammatory response can be provoked, which may progress to sepsis or septic shock (85, 86). 
Sepsis is seen as a life threatening dysregulated inflammatory response to an infection, leading 
to organ dysfunction (86).  
Sepsis is associated with high mortality claiming 11 million deaths worldwide in 2017, 
imposing an immense global burden with an estimated incidence of about 49 million cases 
(87). Sepsis is most commonly caused by pneumonia (88). The earlier a diagnosis can be made 
enabling the initiation of a targeted therapy, the higher are the patient’s chances to survive the 
acute disease (89, 90). However, currently no autonomous and culture-independent laboratory 
method is available to rapidly diagnose sepsis (86, 91, 92). In contrast, diagnostic standards 
rely on several time-consuming cultivation steps, starting with an enriching culture for the 
typically low abundant bacteria in a blood sample, followed by pathogen isolation, 
identification and antibiotic susceptibility determination (86, 91).  
On average, a positive result is obtained after 10 hours incubation in an automated blood culture 
system, with nearly 90 % of positive cultures detected within the first 24 hours of cultivation 
(93). It could however take up to 48 to 72 hours to receive a positive blood culture and up to 
96 hours for an antibiotic susceptibility profile (93, 94). Besides the expenditure of time, 
cultivation steps come with several disadvantages, which is reflected in the high percentage of 
sepsis cases, 30 %, with a negative blood culture (95). Especially slow growing and fastidious 
organisms are prone to cause false negative blood culture results (92). Furthermore, the blood 
volume of the cultures tremendously influences their sensitivity, which is especially critical for 
pediatric samples (92, 96, 97). Beyond that, poly-microbial infections might be misjudged due 
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to the possible outgrowth of one organism that is better adapted to the culturing conditions (98). 
One reason why a cultivation step is still not replaced by an alternative method is the low 
abundance of bacteria in a bacteremic blood sample, which might be as low as 0.5 to a few 
colony forming units (cfu)/mL in adult and pediatric samples (97-99).  
Matrix-associated laser desorption ionization-time of flight (MALDI-TOF) is used for 
pathogen identification from a positive blood culture, and has also been implemented on whole 
blood without incubation (91). In combination with polymerase chain reaction (PCR) analysis, 
it has been shown to yield pathogen identification within 6 hours on whole blood without prior 
cultivation with 81 % sensitivity and 69 % specificity in comparison to conventional pathogen 
cultivation and identification (95). Another example for a rapid bacteria identification method 
from unincubated blood is the SeptiFast® multiplex qPCR assay from Roche. It delivers a 
result in 6 hours directly from 3 mL of blood with a sensitivity of 70 - 100 % for 30 cfu / mL 
and 50 – 100 % for 3 cfu / mL, depending on the investigated bacterial species (100).  
 
PCR based techniques for empirical therapy decision making can deliver additional 
information about presence of investigated resistance genes (91). Due to the high variety of 
possible and emerging antibiotic resistance mechanisms and different degrees of phenotypic 
susceptibility in presence of a genomic resistance marker, molecular biological methods for 
resistance determination are however not a sufficient basis for clinical treatment decisions (92, 
101). One major advantage of culture-based methods is therefore the delivery of an antibiotic 
susceptibility profile which could not yet be replaced by a rapid detection method (92), albeit 
being crucial information because appropriate antibiotic treatment of bloodstream infections is 
associated with lower mortality (102). Furthermore, PCR based methods are sensitive to 
contamination and interference with the abundant human DNA (91, 92).  
1.4 RELEVANT CONCEPTS IN MICROFLUIDICS 
The advent of microfluidics appeared about 30 years ago with the first miniaturized total 
chemical analysis systems (µTAS) (103, 104) wherefore developments in microelectronics, 
molecular biology and analytical methods paved the way (105). Microfluidic systems 
manipulate small volumes typically in the microliter to attoliter range, that are confined in glass 
or polymer channels with cross sectional dimensions in the low micrometer range (105, 106). 
In this small sized world, where surface dominates volume, phenomena other than these we 
experience in our macroscopic world prevail (107, 108). For fluids in microfluidic systems, 
which are usually operated at low Reynolds numbers (Figure 3A) (109), this means that inertia 
is becoming negligible whereas viscosity dominates (107). Fluid and particle movement is 
therefore attributable to very immediate forces and not to resulting momentums of those 
previously applied (108). This results in a laminar flow pattern, where liquids are following 
defined streamlines without mixing in a turbulent manner (Figure 3B). This in turn means that 




Yet, one important prerequisite for precise particle manipulation must be met with a high 
enough convection to overcome the effects of diffusion, i.e. a sufficiently high Péclet number 
(Figure 3C) must be assured (110).  
 
Figure 3 Characteristics of a microfluidic system. (A) Reynolds number (110). (B) Laminar flow profile is characterized by 
maximal velocity in the channel center and zero velocity at the channel walls. Flow lines are shown. (C) Péclet number (110) 
(A, C) Two dimensionless numbers for the characterization of microfluidic systems with ρ…fluid density, u…velocity, 
l…channel length, η…dynamic viscosity, D…diffusivity. 
Microfluidic systems enable a miniaturization of reactions with the advantage of using minute 
amounts of samples and reagents (104, 105, 111). These systems have the potential to be a fully 
integrated lab on a chip, offering fast diagnosis for an affordable price without the requirements 
of expert personal and high-end laboratories (111, 112). This makes microfluidic diagnostic 
assays highly relevant for point of care diagnosis especially for applications in the developing 
world, where the high demands of the resource-limited environments constitute a remaining 
challenge (111, 112). 
Particles suspended in a liquid can be displaced through the impact of an acoustic radiation 
force (Figure 4A), evoked by a sound wave (Figure 4B). Already in 1787, the physicist Ernst 
Chladni demonstrated particle movement in response to acoustic vibration with sand pictures 
on an agitated plate (Figure 4C-J) (113). In acoustic microfluidic systems the force of an 
ultrasonic standing acoustic wave is used to move particles within the generated pressure field. 
This happens due to only intrinsic, physical properties, e.g. size, shape, compressibility and 
density of the particles and the surrounding fluid (114) (Figure 4A).  
 
Figure 4 Acoustofluidics. (A) Formula of the acoustic radiation force Fax with a…particle radius, Eac…acoustic energy density, 
k…wavenumber as a function of the applied frequency divided by the speed of sound in the fluid, z…distance from the pressure 
anti-node, ɸ…acoustic contrast factor is determined by the relation of density and compressibility of the particle and the 
suspending medium (115). (B) Acoustic standing wave used to move particles into the center of the microfluidic channel. (C - 
J) Adapted Chladni figures with sand on a wooden plate actuated with different frequencies (C) 112 Hz (D) 125 Hz (E) 150 




2 LITERATURE REVIEW: THE PNEUMOCOCCAL CELL 
ENVELOPE AND CELL WALL HYDROLYSIS 
2.1 THE CELL ENVELOPE OF STREPTOCOCCUS PNEUMONIAE 
The bacterial cell envelope defines an individual living prokaryote and fulfills a multitude of 
purposes. It must function as a strong and tight cover to withstand the bacterial turgor pressure 
and serve as a shield to protect the organism from hostile environments. Simultaneously to 
providing strength, the shield needs to adapt flexibly to everchanging environments that differ 
for example in osmotic conditions, temperature, and concentrations of harmful compounds. In 
addition, the cell envelope is in constant turnover during growth and is therefore a very variable 
structure. Furthermore, the cell envelope must be permeable for example to nutrients or ions, 
whose gradient is important for the maintenance of the ion motif force (116). The cell envelope 
is therefore essential for the cellular energy balance. Overall, the pneumococcal cell envelope 
is negatively charged. The surface charge is mainly constituted by the usually negative charge 
of the polysaccharide capsule (117), teichoic acids (118), and the cell membrane (119-121). It 
is advantageous for example to establish colonization by avoiding trapping and subsequent 
clearance in the positively charged airway mucous and to evade phagocytosis through 
electrostatic repulsion (29, 48, 117) (Figure 2). The host innate immune system also exploits 
this surface property to establish electrostatic interactions between the negatively charged 
bacterial surface and positively charged antimicrobial peptides (122-124).  
The following paragraphs describe selected components of the pneumococcal cell envelope, 
that are especially relevant for the thesis, starting with the cell membrane and continuing with 
the cell envelope structures that depend on undecaprenyl pyrophosphate (bactoprenyl) carriers 
for their synthesis: peptidoglycan, teichoic acids and the polysaccharide capsule. How cell 
envelope structures are exploited as antibacterial targets is discussed in chapter 2.2. Surface 
exposed proteins, other very important components of the cell envelope, are only mentioned 
briefly here and few other sections of the thesis, but chapter 2.3 deals with selected surface 
exposed proteins, that are cell wall hydrolases in more detail.  
Pneumococcal surface proteins can be membrane associated (lipoproteins), non-covalently 
bound for example to choline residues in teichoic acids, or covalently bound to the 
peptidoglycan with an LPxTG anchor (125-127). Furthermore, non-classical surface proteins 
constitute secreted proteins such as the polyhistidine triad (Pht), and other moonlighting 
proteins that associate with the pneumococcal surface in a to date unknown way (125, 126, 
128). Surface exposed proteins constitute major virulence factors and are of high interest as 
candidates for vaccine antigens to mount an antibody response (48). Their function is diverse 
and includes adhesins, enzymes, transporters, channels, and environmental sensors such as 
two-component systems (129).  
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 The pneumococcal cell membrane 
The main lipid species in the pneumococcal membrane are the anionic phosphatidylglycerol, 
cardiolipin, neutral glycolipids such as diacylglycerol, and the zwitterionic 
phosphatidylcholine (130-132). Studies on the membrane composition in pneumococci are rare 
and therefore knowledge about selected aspects of membrane biology generated through 
investigations of other bacteria are compiled. In gram-positive bacteria, the surface exposed 
membrane bilayer is more negatively charged than those of human cell membranes, where 
anionic lipids are predominantly found in the inner leaflet of the membrane (119-121). The 
properties of lipids are important for the topology, folding and consequently the function of 
membrane proteins (132, 133). The degree of freedom for the movement of phospholipid head 
groups influences membrane fluidity and viscosity, whereas the packing of the lipids is 
determined by the lipid head group and saturation degree of their constituting fatty acids (134, 
135). The biophysical properties of the membrane are carefully monitored, as important 
associated functions such as protein-protein interactions and membrane permeability are 
influenced by them (134). The adjustments of the bacterial phospholipids to changes in 
temperature, osmotic conditions or pH are referred to as homeoviscous adaptation (134, 136, 
137).  
Within a bilayer, lipids are not randomly distributed. Lateral lipid organization can be 
determined by the lipid head group (135). Cardiolipins, for example were found enriched at the 
division septum and the poles of Escherichia coli and Bacillus subtilis (138-140). Likewise, 
non-bilayer forming glycolipids are localized in areas of increased membrane curvature (131, 
141, 142). Anionic lipid microdomain formation by phosphatidylglycerol and cardiolipins have 
been described to determine the topology of protein secretion in the gram-positive coccus 
Streptococcus pyogenes (143). Furthermore, the bacterial membrane is compartmentalized in 
regions of increased fluidity (RIF) (144) and in functional membrane microdomains (FMM) 
that are characterized by a lower fluidity in comparison to the surrounding membrane (135, 
145). The arrangement of the lipids and associated membrane proteins into RIFs in the rod-
shaped B. subtilis is determined by the bacterial actin homologue cell-shape determining 
protein MreB (UniProtKB Q01465) (144), a protein family absent in the coccoid S. 
pneumoniae (146). Membrane fluidity homeostasis is furthermore controlled by bacterial 
flotillins (147). The compartmentalization of the membrane is important for protein 
localization (148) and proper function of cell membrane associated processes, such as 
peptidoglycan synthesis (147, 149, 150).  
 
The building blocks of membrane lipids are fatty acids. Bacterial fatty acid synthesis type II 
(FASII) relies on a multitude of enzymes that elongate the fatty acid chain by two carbons in 
one cycle and thereby differs from eukaryotic fatty acid synthesis type I, which is solely 
accomplished by one multifunctional fatty acid synthase (Figure 5A, B) (151-153). The 
pneumococcal fatty acid synthesis genes are organized in one operon with two binding sites 
for the fatty acid biosynthesis transcriptional regulator FabT (Figure 5A) that regulates fatty 
acid synthesis through feedback inhibition of the pathway`s end product: long chain fatty acids 
 
 11 
bound to acyl carrier protein 1 (Acp1) (154, 155). Fatty acid synthesis is initiated by the acetyl 
coenzyme A (CoA) carboxylase AccABCD that converts acetyl-CoA to malonyl-CoA (Figure 
5B) (153, 156). This step is also the target for biochemical inhibition of the FASII system in 
presence of enough host fatty acids in addition to the transcriptional repression by FabT and 
co-repressor acylated acyl carrier protein 2 (acyl-Acp2) (157-160). Host fatty acids can be 
taken up by the pneumococcus via a fatty acid kinase (Fak) composed of a fatty acid binding 
protein FakB and the ATP binding protein FakA (159, 161, 162) (Figure 5C). S. pneumoniae 
contains three FakB homologues for the acquisition of the whole fatty acid spectrum of 
saturated, unsaturated and polyunsaturated fatty acids available in the human host (159). 
Synthesis of unsaturated fatty acids in S. pneumoniae is carried out by the trans-2, cis-3-
decenoyl-ACP isomerase FabM, and the ratio of endogenously synthesized saturated and 
unsaturated fatty acids is determined by the balance between FabM and the enoyl-ACP 
reductase II FabK activity (154, 163, 164).  
 
Figure 5 Membrane biogenesis in S. pneumoniae. (A) Pneumococcal fatty acid synthesis operon organization. Promoter 
regions are indicated by an arrow, experimentally validated FabT binding sites (▼) (154, 155, 160) and a proposed binding site 
(*) (163) are indicated. (B) Fatty acid synthesis type II is initiated by the tetrameric AccABCD with malonyl CoA as product, 
that malonyl-CoA:acyl carrier protein transacylase FabD further converts to manoyl- ACP, which serves as substrate for the β-
ketoacyl-ACP synthase III FabH and β-ketoacyl-ACP synthase II FabF (134, 153, 156). Straight and branched chain fatty acid 
synthesis from acetyl CoA is initiated by FabH to initiate the elongation cycle of the FASII system (134, 153, 156, 165). Fatty 
acid elongation is continued by β-ketoacyl-ACP reductase FabG and β-hydroxyacyl-ACP dehydratase FabZ (156). For the 
reduction of trans-2-enoyl-ACP to acyl-ACP, S. pneumoniae contains two non-homologous enzymes the enoyl-ACP reductases 
FabI and FabK, which make it refractory to FabI inhibitors such as triclosan (134, 166). Unsaturated fatty acid synthesis is 
carried out by FabM that competes for the trans-2-enoyl-ACP substrate of at least 10 carbons in length with FabK (154, 163, 
164). (C) Host fatty acids can be bound by FakB proteins and after phosphorylation with the help of FakA, serve as substrate 
for the acyl-phosphate-dependent glycerol-3-phosphate acyltransferase PlsY or the phosphate:acyl-ACP acyltransferase PlsX, 
that synthesizes acyl-ACP, which is used by the 1-acyl-glycerol-3-phosphate acyltransferase PlsC to produce phosphatidic acid 
(159, 161, 162, 167, 168). (D) Phospholipid synthesis from glycerol-3-phosphate (G3P) is initiated by G3P acylation through 
PlsY with acyl-phosphate as substrate. The resulting lysophosphatidic acid is further acylated from acyl-ACP acyl donors by 
PlsC to synthesize phosphatidic acid (167, 168). (E) Phosphatidic acid can be further modified to phosphatidylglycerol through 
enzymatic conversion by the phosphatidate citidylyltransferase CdsA, phosphatidylglycerophosphate synthase PgsA and the 
phosphatidylglycerophosphate phosphatase Pgp (130, 169). Cardiolipin (diphosphatidylglycerol) is synthesized by the 
cardiolipin synthetase Cls from two phosphatidylglycerol species (130). (F) Glycolipid synthesis is catalyzed by a yet 
unidentified glycosyltransferase for monoglycosyl diacylglycerol (GlcDAG) synthesis, while galactosyl-glucosyl-
diacylglycerol (GalGlc DAG) is synthesized by the GalGlc DAG synthase CpoA (131, 142) (G) Phosphatidylcholine presence 
in the pneumococcal membrane has only recently been described and shown to commence at the host derived metabolites 
glycerophosphocholine or lysophosphatidylcholine that are acylated by yet uncharacterized acyltransferases (130).  
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The pneumococcus utilizes the among gram-positive bacteria widespread PlsX / PlsY / PlsC 
route for phosphatidic acid synthesis from glycerol-3 phosphate (Figure 5D) (167, 168). 
Phospholipid head group diversity is established by subsequent enzymatic actions (Figure 5E-
F), except for phosphatidylcholine biosynthesis, where extracellular glycerophosphocholine 
and lysophosphatidylcholine are acylated by yet unidentified acyltransferases (Figure 5G) 
(130). 
 The pneumococcal cell wall 
The pneumococcus appears typically in the shape of a diplococcus of about 1 µm in diameter, 
but is also found as a single coccus or in chains (170), which provides advantages in systemic 
infection or colonization respectively (171, 172). The bacterial morphology is determined by 
the peptidoglycan architecture. Atomic force microscopy of group B Streptococci revealed a 
net-like structure of the coccoid peptidoglycan, with parallel oriented glycan strains crosslinked 
to a varying degree with peptides resulting in bands and pores (173). However, the 
peptidoglycan net is not rigid, but rather a dynamic hydrogel that resists the turgor pressure of 
the bacterial cell and responds to changes in osmotic and pH conditions (174, 175). Recent 
observations in the rod-shaped B. subtilis and spherical S. aureus revealed a difference in 
peptidoglycan architecture in the plane perpendicular to the cell membrane, where the newly 
formed peptidoglycan is of higher density and organization than the mature peptidoglycan on 
the cell surface (175). The typical ovococcal shape of the pneumococcus is maintained through 
adjacent septal and peripheral peptidoglycan synthesis during cell division (176). The current 
model proposes that proteins responsible for elongation (elongasome) and division (divisome) 
form a highly coordinated super-complex at the pneumococcal mid-cell (76). Cell wall 
hydrolases are involved in the remodeling of the newly synthesized peptidoglycan, whereas in 
contrary to rod-shaped bacteria like B. subtilis, the old peptidoglycan of the inherited 
hemisphere in pneumococcal daughter cells is not subjected to extensive turnover (177). 
The main biosynthesis steps of pneumococcal peptidoglycan are conserved in gram positive 
bacteria (Figure 6A), and so are the building blocks such as the glycan backbone and amino 
acids in D- and L-conformation of the crosslinking peptides (Figure 7A) (178, 179). There are 
however many variations to the peptidoglycan fine structure, depending on the species, its 
growth state and prevailing living conditions (179). With a minimal length of 25 disaccharide 
units of the glycan backbone, the pneumococcus has much longer polymers of alternating N-
acetylmuramic acid (MurNAc) and N-acetyl glucosamine (GlcNAc) (178) than S. aureus 
where six disaccharide units are majorly found (174). The pneumococcal cell wall was found 
to be 16 nm to 25 nm thick (180). Crosslinking of the glycan chains with peptides is important 
for a proper function of the cell wall. During exponential growth about 50 % of the 
characterized muropeptide fraction of pneumococcal peptidoglycan (71.4 %) were cross-linked 
to dimers or trimers (178), which indicates a lower degree of crosslinking than typically found 
in S. aureus (174, 179, 181). Crosslinking can be achieved directly via peptide bonds or di-
peptide bridges of L-Ser-L-Ala or L-Ala-L-Ala (Figure 7A), which are abundantly found in 
the peptidoglycan of penicillin resistant strains (77, 179, 182). A prerequisite for peptide 
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crosslinking and proper cell function is lipid II amidation in the cytoplasm (183, 184) (Figure 
6A). The peptides of the pneumococcal peptidoglycan prevail as tripeptides, as the result of 
cell wall hydrolase function (Figure 7A), but are also rarely found as tetrapeptides and 
pentapeptides (178). After synthesis, the degree of acetylation of the glycan backbone can be 
modified, thereby for example conferring resistance to the abundant mucosal cell wall 
hydrolase lysozyme, which constitutes an immune evasive strategy of the pneumococcus 
(Figure 2) (53).  
 
As for most gram-positive bacteria, the pneumococcal cell wall is decorated with teichoic acids 
(wall teichoic acids, WTA), which can also be linked to a lipid anchor in the cell membrane 
(lipoteichoic acids, LTA). In comparison to teichoic acids of other gram-positive bacteria, 
pneumococcal teichoic acids have a more complex composition (118, 185) (Figure 6B). WTA 
and LTA are synthesized in the same pathway and only differ in their cell envelope anchor, 
and they contain ChoP (186). S. pneumoniae incorporates ChoP in the cell envelope and is 
auxotroph for choline (186-188). Choline can be replaced by the structurally similar amino 
alcohol ethanolamine to support pneumococcal growth (189). However, those growth 
conditions result in several physiological alterations in the pneumococcus, such as the 
formation of long chains or the loss of typical lysis phenotypes (Figure 7B) (186, 189). 
Phenotypes also observed in mutants which lost the nutritional requirement for choline and the 
ability to decorate teichoic acids with ChoP (190-192). Choline independence can be achieved 
through the acquisition of a point mutation in the teichoic acid flippase TacF (Figure 6B), 
which confers extended substrate specificity also for non - ChoP containing teichoic acids, 
showing that teichoic acid synthesis independent of their ChoP content is essential (190, 193). 
Even though absence of choline can provide growth permissive conditions in vitro, 
incorporation of choline into teichoic acids has been shown to substantially reduce 
pneumococcal virulence (194). ChoP for example enables the binding to the PFAR, as it 
constitutes a part of the natural ligand, representing a strategy for epithelial cell invasion 
(Figure 2) (51). Interestingly, other common opportunistic pathogens that colonize the 
nasopharynx, like N. meningitidis and H. influenzae, also incorporate choline in their cell 
envelope, indicating the relevance of choline in the niche (195, 196). It is however only S. 
pneumoniae and closely related streptococcal species from the mitis group that incorporate 
choline in their teichoic acids, which is important for example to assure substrate access of 
choline binding cell wall hydrolases (197). Also, known virulence factors are among the 
pneumococcal choline binding proteins, for instance CbpA (Figure 2) or the major autolysin 




Figure 6 Cell envelope biosynthesis pathways that rely on undecaprenyl pyrophosphate carriers. (A) Peptidoglycan 
synthesis commences with the two-step enzymatic conversion of uridine diphosphate (UDP) GlcNAc to UDP-MurNAc 
catalyzed by the UDP-acetylglucosamine-enolpyrovyl-transferase MurA and the UDP-acetylenolpyruvylglucosamine 
reductase MurB (198, 199). Through the combined action of amino acid ligases and racemases, a pentapeptide is added to UDP-
MurNAc (146). The integral membrane enzyme phospho-N-acetylmuramoyl-pentapeptide transferase MraY catalyzes the 
addition of UDP-MurNAc-pentapeptide to undecaprenyl-phosphate (C55-P) to form lipid I (199). Lipid II is formed when 
UDP-GlcNAc is attached by the undecaprenyldiphospho-muramoylpentapeptide β-N-acetylglucosaminyltransferase MurG 
(199). Subsequent amidation of Lipid II by the lipid II isoglutamyl synthase MurT / GatT (UniProtKB Q8DNZ9 / 
AOAOH3JN63), is crucial for efficient peptidoglycan crosslinking (183, 184). Diamino branches for the formation of peptide 
bridges in the peptidoglycan are added by MurM and the aminoacyltransferase MurN (UniProtKB: Q9L446) to the lipid II 
stempeptide (76, 200).The molecule is flipped to the outer leaflet of the plasma membrane by the cell division protein FtsW, 
that is proposed to facilitate transmembrane diffusion of Lipid II (146, 201). On the outer membrane leaflet, Lipid II becomes 
a substrate for class A bifunctional PBPs that mediate transglycosylation as well as transpeptidation or class B PBPs that mediate 
transpeptidation of septal and peripheral peptidoglycan (76, 176). Recycling of the undecaprenyl pyrophosphate (C55-PP) is 
mediated by phosphatases such as YbjG, and the C55-P carrier is translocated to the cytoplasmatic side of the membrane by a 
to date unknown mechanism (146). Here one model for the gram-positive peptidoglycan with glycan chains oriented 
perpendicular to the cell membrane is depicted (202, 203). (B) Teichoic acid synthesis is catalyzed on the undecaprenyl 
phosphate carrier by a manifold of enzymatic synthesis steps in the cytoplasm and the membrane, some of which have not yet 
been biochemically characterized (185). Pneumococcal teichoic acids consist of typically 4 to 7 repeating units of the unique 
sugar 2-acetamido-4-amino-2,4,6-trideoxy-D-galactose (AATGal), followed by one glucose molecule as well as ribitol that can 
be modified with a D-alanine to increase surface charge, and two N-acetyl-galactosaminyl (GalNAc) residues that are decorated 
with ChoP residues (76, 118, 185, 204, 205). Choline from the host is imported through the transmembrane protein LicB and 
activated by the kinase LicA and cytidyltransferase LicC (185). The complex teichoic acid polymer is translocated to the outer 
leaflet of the membrane by the transmembrane teichoic acid repeat unit transporter TacF (UniProtKB B0BEX9) (185). 
Synthesis of wall teichoic acids (WTA), by attachment of the TA polymer to 15 - 30 % of MurNAc residues of the peptidoglycan 
(200) are likely accomplished by phosphotransferases of the LCP (LytR, CpsA, Psr) family (185). Attachment of the TA 
polymer to the glycolipid anchor to form lipoteichoic acids is likely mediated by the putative lipoteichoic acid ligase TacL 
(206). (C) Capsular polysaccharide synthesis principal steps are shared among serotypes that assemble their capsule utilizing 
polysaccharide polymerase Wzy polymerization (207). Capsular biosynthesis commences with the transfer of a sugar moiety 
to the undecaprenyl phosphate carrier by the initiating glycosyl transferase (Tigr4: capsular polysaccharide biosynthesis protein 
Cps4E / WciI, UniProtKB Q7WVW9) (208, 209) to form lipid Icap (210). Continuing glycosyltransferases synthesize one 
serotype specific polysaccharide unit in the cytoplasm. The repeat unit transporter Wzx transfers the polysaccharide unit to the 
outer membrane leaflet and Wzy catalyzes the polymerization of those polysaccharide units (208). LCP family proteins or Wzy 
are proposed to covalently ligate the polymer to the peptidoglycan (211, 212). The capsular polysaccharide of serotype 4 is 
depicted (213). 
 The pneumococcal polysaccharide capsule 
The capsule is a polysaccharide structure that defines the more than 98 pneumococcal 
serotypes (29). It is composed of a variety of sugar moieties and additional constituents such 
as pyruvate, ribitol and for serotypes 15F, 24A, 27, 28A, 28F, 32A and 32F also choline (124, 
208). The differences in polysaccharide composition are reflected in variations of the 
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capsular biosynthesis gene locus. Except for serotype 3 and 37, which synthesize their 
capsular polysaccharide in a synthase dependent way, most other capsules are synthesized 
through Wzy polymerization (124, 214, 215) with the principal biosynthetic steps depicted 
in Figure 6C. The entire capsular genetic locus for all serotypes, except of serotype 37 (215), 
is embedded between the same genes (207). Wzy- dependent capsular biosynthesis genetic 
loci contain a common cluster of four genes cpsA-D, with cpsB-D regulating capsule 
production (208). The fifth gene of the locus encodes for the initiating sugar transferase 
(Serotype 4: cps4E / wciI) which is, as the following genes in the capsular locus, serotype 
specific (207). The capsule can be 200 to 400 nm thick and therefore makes it the most 
dominant cell envelope structure of the pneumococcus (180). Pneumococcal capsules are 
usually negatively charged, only a few are of nearly neutral charge (117). The capsule is a 
major virulence factor of the pneumococcus. Loss of the capsular polysaccharide through 
enzymatic degradation, markedly reduced S. pneumoniae serotype 3 pathogenicity in a 
mouse model for invasive disease (216). The capsule facilitates evasion of phagocytosis, 
shields antigens, reduces complement deposition and prevents receptor interaction of 
deposited complement (48). It has also been reported to increase tolerance to cell wall 
synthesis inhibiting antibiotics (217).  
2.2 MEMBRANE AND UNDECAPRENYL PYROPHOSPHATE TARGETING 
ANTIBIOTICS 
Detergents interact with the membrane through amphiphilic interactions, with no distinction 
between prokaryotic or eukaryotic membranes. Essentially, the surfactant is inserting into the 
membrane and accumulates to a threshold concentration when mixed micelles of membrane 
lipids and surfactant are formed (218). Membrane targeting antibiotics however can 
specifically alter physiological properties of the bacterial membrane, such as lateral lipid 
organization, membrane curvature, as well as fluidity by causing aberrant lipid packing or 
clustering (119). The effect can be exerted either directly or indirectly by binding to a lipid 
species (119).  
An example for direct lipid binding is the plant derived acylphloroglucinol rhodomyrtone, that 
exerts antibacterial activity towards gram-positive bacteria by binding to the headgroups of 
phospholipids (219). This transient interaction causes a distortion of the phospholipid 
headgroup packing, which provokes overall membrane fluidization, permeability alteration and 
increased curvature, which ultimately leads to vesicle formation (219). Rhodomyrtone is the 
first described membrane targeting molecule that exerts activity without integrating into the 
membrane (219). How specificity towards prokaryotic membranes is established remains to be 
studied, but rhodomyrtone displays low eukaryotic cell toxicity in vitro on erythrocytes (220, 
221), as well as in vivo in caterpillars, zebrafish and mice (220), and was effective in a zebrafish 
model for pneumococcal infection (219). 
 
Cationic antimicrobial peptides are a component of the innate immune response that target the 
bacterial cell membrane. Specificity is provided by the electrostatic interaction between 
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negatively charged membranes and amphipathic cationic antimicrobial peptides, where some 
of them undergo conformational changes after insertion into the lipid environment (121). 
Insertion of a critical amount of peptides destroys bacterial membrane integrity (121).  
 
Moreover, most antimicrobial peptides also bind to bactoprenyl carried cell envelope 
precursors in the bacterial membrane (222). Similarly, antibacterial agents such as nisin, 
teixobactin, and daptomycin interact with undecaprenyl pyrophosphate coupled cell envelope 
precursors and the bacterial membrane. The lantibiotic nisin binds to the pyrophosphate moiety 
of lipid II and lipid IIIWTA, and requires the first sugar moiety to establish high affinity 
interactions (223). Accumulation of nisin, bactoprenyl carried cell envelope precursor 
complexes, results in membrane pore formation (222, 223). Teixobactin, which was isolated 
with the iChip technology for under laboratory conditions uncultivable soil bacteria, anchors 
in the membrane and binds to the pyrophosphate moiety of lipid II, but also interacts with the 
adjacent sugar moiety of lipid II or lipid IIIWTA (224, 225). However, those interactions have 
been shown to be rather weak in anionic membranes, and bactericidal activity is mainly exerted 
through clustering and consequential sequestration of cell envelope synthesis precursors (225). 
Complex formation has also been shown for Ca2+ mediated daptomycin oligomers, which 
interact with phosphatidylglycerol and bactoprenyl coupled cell envelope precursors to stall 
cell envelope synthesis (149). Furthermore, membrane integrity interference was described for 
the lipoglycopeptides oritavancin and telavancin that, as the glycopeptide vancomycin, bind to 
the di-alanine moiety of the stem peptide of lipid II, but additionally anchor in the membrane 
via a lipophilic moiety (222, 226, 227). To conclude, targeting bactoprenyl carried cell wall 
precursors can result in pleiotropic effects beyond those resulting from target sequestration, 
such as interference with membrane integrity and membrane protein localization (223).  
 
Through cessation of the supply of building blocks, membrane synthesis can be inhibited by 
FASII inhibitors. Nearly all enzymes of the pathway (Figure 5B) can be inhibited (134, 153, 
228), and a new FabI inhibitor (Afabicin) is currently in clinical development (22).  
2.3 CELL WALL HYDROLASES AND LYSIS PHENOMENA OF 
STREPTOCOCCUS PNEUMONIAE 
Cell wall hydrolases are ubiquitous in bacteria, as they are essential for growth and cell division 
(Figure 7) (229, 230). For S. pneumoniae several peptidoglycan hydrolases are described to 
date (Figure 7A) (200), among them the major pneumococcal autolysin LytA. The N-
acetylmuramoyl-L-alanine amidase LytA is involved in the various autolysis phenomena of 
pneumococci (Figure 7B), but also contributes to daughter cell separation (231-233), which is 
mainly accomplished by the non-autolytic peptidoglycan hydrolase LytB (232, 233) and the 
vaccine candidate PcsB (234-237). LytB deficient strains form long chains (233), and PcsB 
activity is essential for cell division (234, 235, 238). Proper division in the pneumococcal mid-
cell during growth also requires the action of the carboxypeptidases PBP3 (DakA) (239) and 
DakB (240). The tripeptide containing peptidoglycan, formed by the consecutive action of 
PBP3 and DakB, is a prerequisite for pneumococcal morphology, vancomycin resistance and 
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invasive disease potential (76, 200, 241). Aberrant transpeptidation resulting from an altered 
substrate availability in absence of carboxypeptidase activity, might be the cause of the 
anomalous peptidoglycan architecture (239-241).  
Furthermore, several other putative cell wall hydrolases with a suspected role in cell division 
have been identified, but are not yet fully characterized (235, 240, 242). Among them is a 
putative N-acetylmuramidase (locus tag SPD_1874) or a putative shape, elongation, division 
and sporulation (SEDS) family protein (locus tag SPD_0703) (240). Additionally, non-
covalent GlucNAc binding lysin motif (LysM) containing proteins are found among bacterial 
cell wall hydrolases (243, 244), that supposedly substitute the enzymatic actions of 
pneumococcal PcsB in cell division, as their augmented expression has been found in pcsB 
knockout strains (235). The newly identified lytic transglycosylase MltG indicates that LysM 
motif containing proteins might also play a role in peripheral peptidoglycan synthesis (242, 
245).  
It is common in bacteria to express multiple cell wall hydrolases with similar activities at which 
redundancy emphasizes their importance for cell physiology (229, 230, 240). A large share of 
to date characterized pneumococcal cell wall hydrolases include choline binding proteins that 
associate with the cell wall through non - covalent binding to ChoP (246, 247). The presence 
of ChoP in teichoic acids is therefore important for their function in cell separation and lysis 
(189). However, besides redundancy in enzymatic activity, diversity in cell envelope binding 
is conceivable for maintenance of cell wall hydrolase mediated peptidoglycan remodeling. The 
above-mentioned putative cell wall hydrolases, with the among bacteria widely distributed 
non-covalent peptidoglycan binding motif LysM (243, 244), might be an example thereof.  
During in vitro growth, pneumococcal cultures undergo spontaneous autolysis in the nutrient 
depleted stationary growth phase (Figure 7B). This is proposed to be a phenomenon of 
altruistic suicide, which is undergone by a subpopulation of bacterial cells to provide nutrients 
and reduce the cell number, so that a small subpopulation of cells can survive a longer period 
of nutritional stress (248, 249). This might be especially important in the nutrient scarce 
nasopharynx (250), and S. pneumoniae shares the phenotype of spontaneous stationary phase 
lysis with common niche colonizers N. meningitidis and H. influenzae (37). Growth inhibition 
evoked by cell wall targeting antibiotics such as penicillin (Figure 7B) also triggers the onset 
of autolysis (251), in contrary to erythromycin and tetracycline that inhibit protein synthesis, 
or the RNA synthesis inhibiting rifampicin (252). Antibiotic induced autolysis in early 
logarithmic phase could constitute an altruistic stress response akin to the stationary phase 
triggered lysis (249). Here, benefits of altruistic autolysis apart from nutrient homeostasis might 
take effect, as removal of damaged cells can be beneficial for the population, analogous to the 
programmed cell death in eukaryotes (249, 253). Furthermore, it can be a way of removing 
especially fast-growing mutants as they are most susceptible to growth inhibitors (249) in favor 




Stress conditions that infer DNA damages can provoke pneumococcal lysis due to the 
activation of temperate phages, which have been integrated in the pneumococcal chromosome 
and entered the lytic cycle (255). Phages lyse their host pneumococcal cells by a choline 
binding N-acetylmuramoyl-L-alanine amidase that closely resembles the bacterial LytA, which 
is exported by two phage genome encoded holins (255).  
 
The effects of the multicellular behavior of bacteria in the case of lysis are however not only 
of altruistic nature. During the state of natural transformability, competent pneumococci 
commit fratricide on non-competent sibling cells in the population (248, 256). Fratricidal 
allolysis is mediated by the endopeptidase CbpD, but also the activity of LytA and LytC from 
the assassinated cells are required for their lysis (Figure 7A) (257). Competent bacteria express 
an immunity protein ComM that protects them from committing suicide (258). How CbpD 
activity is inhibited by ComM is not yet understood, nevertheless modulation of peptidoglycan 
is suspected as cells overexpressing ComM displayed aberrant cell morphology (259). 
Additionally, two lipophilic competence induced peptide bacteriocins CibAB initiate allolysis, 
likely by inserting into a non-competent sibling membrane upon close contact (248, 260). 
Competent cells are protected by the CibC immunity factor (260).  
 
Figure 7. Peptidoglycan hydrolases and lytic events in the in vitro growth phases of Streptococcus pneumoniae. (A) The 
glycosidic bonds of the glycane backbone (MurNAc, GlcNAc) are hydrolyzed by cell wall glycosidases (261). In S. pneumoniae 
two cell wall glycosidases are known: the endo-β-N-acetylglucosaminidase LytB that cleaves the polysaccharide after GlcNAc 
(230, 232) and the N-acetyl-β-D-muramidase / lysozyme LytC which hydrolyzes the glycosidic bond after MurNAc (230, 262). 
An additional putative glycosidase, the lytic transglycosylase MltG, has been identified (242, 245). Lytic transglycosylases also 
cleave the glycosidic bond after MurNAc but unlike lysozyme, hydrolysis results in a terminal anhydro-ring modified MurNAc 
residue (230, 261). The N-acetylmuramyl-L-alanine amidase LytA cleaves the amide bond between L-alanine and MurNAc 
(230, 252, 263). Both choline binding protein CbpD and the protein required for cell separation PcsB contain a cysteine- and 
histidine-dependent aminohydrolases / peptidases (CHAP) domain, a feature of amidases and endopeptidases (230, 236, 237, 
264, 265). For CbpD, cell wall hydrolase activity has been demonstrated (265), whereas no such could be measured in vitro for 
PcsB (235), likely because of the requirement for activation through the cell division protein membrane bound ABC transporter 
FtsXE complex (200, 236, 264). The penicillin binding protein PBP3 (also called D, D-carboxypeptidase DacA) and the L, D 
carboxypeptidase DacB are carboxypeptidases that trim the newly synthesized pentapeptide to a tetrapeptide (PBP3) and 
tripeptide (DacB) (240, 241). Except for those marked with an asterix, pneumococcal cell wall hydrolases are choline binding 
proteins (246, 247). (B) The typical growth curve of S. pneumoniae Tigr4 strain in in vitro culturing conditions in the laboratory. 
At the beginning of the exponential growth phase the bacteria are naturally competent for a limited time (248). Allolysis due to 
fratricide is occurring during the competence window (248), the lytic changes are not recordable with the resolution of the 
spectrophotometric optical density (OD) determination. Autolysis is induced in response to cell wall synthesis inhibiting 
antibiotics such as penicillin, that have been administered in the early logarithmic growth phase (indicated by an arrow) and is 
readily recordable with a decrease in OD. In stationary phase, pneumococci undergo autolysis, which onset is dependent on the 
serotype and growth conditions. 
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Knowledge about the regulation of pneumococcal cell wall hydrolases is scarce. The best 
studied example for regulation in S. pneumoniae is the major autolysin LytA. Interestingly, 
pneumococcal cells are protected from the action of LytA during exponential growth, which 
only induces lysis upon growth inhibition of antibiotics or in stationary phase (252, 266). In 
exponential phase LytA is primarily located intracellularly and cell surface bound 
concentrations only increase before the onset of stationary phase autolysis (252, 266). LytA 
requires access to a big substrate interface and is proposed to act on the newly synthesized 
peptidoglycan (252, 267, 268). This is supported by the observation that LytA binds to nascent 
teichoic acids at the mid cell (266). Access to the substrate in exponential phase is hindered by 
the sequestration of LytA from the cell wall through binding to lipoteichoic acids (269). 
Furthermore the acetylation of peptidoglycan could exclude the concurrent attachment of a 
teichoic acid to the acylated MurNAc and may promote peptidoglycan maturation through 
efficient transpeptidation (270). In stationary phase the balance of lipoteichoic acid to wall 
teichoic acid synthesis is skewed as TacL is degraded by the membrane anchored ATP 
dependent zinc metalloprotease FtsH, which can facilitate substrate access for LytA (269). 
Furthermore, the lack of MurNAc O- acetylation has been shown to sensitize S. pneumoniae 
to penicillin and LytA actions during exponential growth (270).  
How substrate access for LytA is regulated is not yet elucidated, although observations have 
been made. One of them is the involvement of Vex3 of the Vex123 ABC transporter in 
vancomycin tolerance through reduced autolysis (271), which has been proposed to export a 
peptide Pep27 that functions as quorum sensing molecule for cell density (272). The mechanism 
of autolysis regulation is however not clear as reported observations (272, 273) have been 
affected by erythromycin in the growth medium (271, 274). Furthermore, as programmed cell 
death, stationary autolysis has been proposed to be regulated by toxin – antitoxin systems (248). 
Also, two-component systems might regulate autolysis activation in response to environmental 
signals. The cell envelope stress sensing two-component system LiaSFR has a protective effect 
on the pneumococci during hydrolase (CbpD, LytC and LytA) provoked cell wall stress in the 
course of competence (275). Absence of the two-component system CiaRH increased 
pneumococcal sensitivity to cell wall synthesis inhibitor induced lysis (276). Independent of 
the exact regulatory mechanism of stationary phase autolysis activation, antibiotic induced 








3 RESEARCH AIMS 
The research efforts included in the thesis aimed in the broadest sense for a contribution to the 
armors race in combating antibiotic resistance in the areas of therapeutic and diagnostic 
interventions.  
 
Paper I and II describe the characterization of two bactericidal chemical classes respectively, 
that were discovered in a phenotypic screen. The studies aimed to elucidate the bacterial target 
of the chemicals and describe their mechanism of bactericidal action.  
 
Paper III aspired to develop a sample preparation process employing microfluidic label free 
particle operations for the decomplexation of bacteria containing blood with the aim to 







4 MATERIALS & METHODS 
4.1 BACTERIA AND GROWTH CONDITIONS 
The thesis is relying on S. pneumoniae D39 (serotype 2) and Tigr4 (T4, serotype 4) wildtype 
strains as model organisms. A variety of D39 and T4 derivative mutant strains were 
constructed, where a gene of interest was replaced with an antibiotic resistance cassette. 
Additionally, THCz sensitivity of multi–antibiotic resistant pneumococci from the 
Pneumococcal Molecular Epidemiology Network (PMEN) (277) was determined in paper II.  
S. pneumoniae was cultured on Columbia blood agar plates over night at 37 ºC and 5 % CO2. 
The standard growth and assay medium for the pneumococcus was Casitone and Yeast extract 
(C+Y) medium, supplemented with 9 % glucose bouillon and 1 % horse serum, which provides 
optimized conditions for the fastidious organism. Todd Hewitt medium with 0.5 % yeast extract 
(THY) was employed when required, such as for comparing THCz sensitivity of S. pneumoniae 
with other bacterial species in paper II. Those media were adapted to establish specialized 
growth conditions, for example defined extracellular fatty acid concentrations in paper I or 
selective media for obtaining THCz-tolerant mutants in paper II. For the construction of 
pneumococcal mutant strains, transformation was carried out in Tryptic Soy broth (TSB) with 
additional glycerol (10 %) and CaCl2 (0.01 %) (252).  
 
Other gram-positive and gram-negative bacterial species were grown in Mueller-Hinton broth 
(MHB) or cation-adjusted Mueller-Hinton broth (CAMHB), TSB, Brain Heart Infusion (BHI) 
medium or THY medium with adjustments as stated in the respective papers. CAMHB is the 
standard medium for MIC determination defined by the Clinical and Laboratory Standards 
Institute (CLSI) and requires addition of lysed horse blood to ensure good growth of S. 
pneumoniae (278). Both investigated screening hits (described in paper I and paper II) did 
however display a degree of plasma protein binding (279) and therefore, the standard media 
for compound characterization was kept to supplemented C+Y medium, as it was used in the 
screening campaign. 
4.2 PHENOTYPIC SCREEN FOR THE DISCOVERY OF BACTERICIDAL 
ANTIBIOTICS 
The phenotype employed in the screen was cell wall hydrolase mediated lysis of S. pneumoniae 
assessed by turbidimetry. Measurement of the optical density (OD) of a bacterial culture at 600 
nm provided an easy and scalable readout for the evaluation of a compound`s effect on the 
bacteria. Cell wall synthesis inhibition induces pneumococcal autolysis (251, 252). As the cell 
wall is degraded, osmotic lysis causes a release of the intracellular content into the medium, 
resulting in a measurable decrease in OD of the culture. As detergents such as deoxycholate or 
Triton X-100 may also activate autolysin mediated lysis (189, 252), it is important to exclude 
compounds with such undesired properties. The screen is described in more detail in paper II. 
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 Characterization of screening hits 
Determination of cell wall hydrolase mediated lysis 
For the confirmation of cell wall hydrolase involvement in bacterial lysis and the corresponding 
OD decrease, choline chloride concentration in the growth medium of a lytA gene replacement 
mutant was increased. Thereby all choline binding cell wall hydrolases were decoyed from 
binding to the choline residues on the pneumococcal teichoic acids (280). Consequently, they 
could not execute their enzymatic activity on the cell wall and the resulting absence of a 
prominent decrease in OD was attributed to the involvement of choline binding cell wall 
hydrolases in pneumococcal lysis upon chemical and antibiotic treatment. A complementary 
assessment of viability through counting colony forming units after compound treatment 
allows for the judgement of the cell wall hydrolase independent activity of the compound. 
Penicillin for example does then, albeit considerably weakened, still exert bactericidal activity 
(281). Furthermore, transmission electron microscopy (TEM) was employed to confirm the 
involvement of cell wall hydrolases in THCz mediated lysis in paper II.  
Minimal inhibitory and minimal lytic concentration (MIC/ MlytC)  
In the thesis two key figures, MIC and MlytC, for antibacterial activity of the screening hit 
compounds and their analogs were determined for characterization and structure activity 
relationship studies. The key differences between the methods are the inoculum size as they 
are ~ 5x105 colony forming units (cfu) / mL for the MIC and ~ 3x107 cfu / mL for MlytC 
determination of S. pneumoniae D39. Furthermore, bacteria for MlytC assays were at the start 
of their exponential growth phase, whereas for MIC determination the chemicals were added 
directly after dilution of the pre-culture, likely catching the bacteria in the lag phase of their 
growth. The duration of incubation differs from about one hour for MlytC to 20 hours for MIC 
determination. For both assays the result is measured optically, with a spectrophotometric 
turbidity recording at 600 nm for MlytC and visual judgement by the eye for MIC 
determination. While the MIC is a standard value in microbiology, we have introduced MlytC 
for the characterization of 2CCA-1 in paper I, to account for the lysis inducing response in 
exponential growth phase, which would have been disguised in the incubation period of MIC 
assays due to the exceptionally fast resistance development.  
Identification of membrane interactions 
To determine effects of 2CCA-1 treatment on membrane fluidity in paper I, generalized 
polarization of the membrane probe laurdan was recorded. The fluorescence properties of 
laurdan are sensitive to changes in the number and agitation of water molecules in the 
membrane-liquid interphase, which gives information about the packing of phospholipid head 
groups that also reflects the saturation degree of their fatty acid chains and thus membrane 
fluidity (150, 219, 282, 283). The organic solvent benzylalcohol is a known membrane fluidizer 
and was used as control treatment, along with dimethylsulfoxid (DMSO) as solvent control 
(284). As 2CCA-1 needed actively growing cells to exert activity, which would not have been 
assured in the staining buffer (PBS with 2 % glucose), we performed an end-point measurement 
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of laurdan generalized polarization. Bacteria were stained with laurdan after about 30 minutes 
incubation with the chemicals, shortly before lysis occurred. However, benzyl alcohol and 
2CCA-1 induced membrane fluidity changes might differ in their kinetics, which cannot be 
recorded in the employed experimental setup. Organic solvents cause an abrupt change in 
membrane fluidity which bacteria counteract with rapid modifications of membrane 
phospholipids e.g. cis-trans isomerization of unsaturated fatty acids (134, 150). In comparison, 
slower kinetics are expected for changes in membrane fluidity exerted by de-novo synthesized 
phospholipids, as it could apply to 2CCA-1 (134, 150).  
Compound challenge of non-growing bacteria in their stationary phase was performed to assess 
membrane homeostasis perturbation. Bactericidal activity of daptomycin for non-growing 
stationary phase S. aureus was shown (285) and the phenotype has been exploited in a screen 
for membrane targeting chemicals in B. subtilis (286). Membrane pore formation, as caused by 
the lantibiotic nisin (222), was examined through the quantification of cellular potassium 
release in paper II.  
Eukaryotic cell toxicity 
Toxicity of THCz screening hit compounds and analogs on eukaryotic cells were assessed in 
vitro on A549 lung epithelial cells. The assay was conducted in the cell growth medium 
Roswell Park Memorial Institute (RPMI) supplemented with 10 % fetal bovine serum (FBS) 
with cells seeded to a concentration of 1x105 cells / mL or 1x106 cells / mL. For initial structural 
toxicity relationship estimation, analogs that displayed activity against S. pneumoniae were 
tested with a standard concentration range of 100 µM, 50 µM, 25 µM and 12.5 µM. An adjusted 
and more narrow concentration range was subsequently tested for a selection of compounds to 
determine the 50 % inhibitory concentration IC50. Viability of A549 cells was judged through 
the capacity of metabolically active cells to reduce resazurin to resorufin, causing a measurable 
color change. 
 Target identification and mechanism of action description 
Pneumococcal mutant strains  
Spontaneous resistant 2CCA-1 mutants were isolated after over-night incubation of plated 
cultures, that were challenged with 2CCA-1 in the early exponential growth phase (paper I). 
Isolation of THCz resistant mutants in paper II was attempted through continuous sub-
cultivation of S. aureus in a broth microdilution assay with sub-inhibitory THCz-1 
concentrations adapted from Ling et. al. for teixobactin resistance development (224). 
Furthermore, THY plates were developed that allowed both the growth of the fastidious S. 
pneumoniae and activity of THCz-1. Continuous cultivation on THY plates containing readily 
incrementing concentrations of THCz-1 was performed at 37 ºC and 5 % CO2. Genomic DNA 
was isolated from resistant or tolerant strains and whole genome sequencing was performed. 
Gene replacement mutants were constructed to confirm the underlying genotype of resistant 
mutants and guide target identification.  
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Total lipid analysis 
Lipidomic analysis was performed on 2CCA-1 treated wildtype and a spontaneous resistant 
mutant strain to determine the mechanism of action of the screening hit (paper I). Isolated 
lipids were analyzed in ultra-high-performance liquid chromatography and subsequent tandem 
mass spectrometry. The lipid profile was subjected to targeted analysis and the molecular 
features unique to the 2CCA-1 treated sensitive pneumococci, were subjected to targeted 
tandem mass spectrometry for further characterization. 
Gene expression and protein-DNA interaction determination 
Gene expression was determined via reverse transcriptase quantitative PCR to explain the 
2CCA-1 resistance profile in paper I. For the examination if the regulation of the 
transcriptional regulator FabT is exerted through direct binding to the promoter of fakB3, an 
electrophoretic mobility shift assay (EMSA) with radioactively labelled probes was performed.  
Assays for THCz target identification 
Whole cell experiments and biochemical assays were performed for THCz target identification. 
B. subtilis reporter strains were employed in a β-galactosidase assay to investigate 
macromolecular synthesis pathway (cell wall, nucleic acid and protein synthesis) inhibition by 
THCz. This was complemented with a microscopical approach to examine B. subtilis cell wall 
integrity after THCz treatment in comparison to known antibiotics. The concentration of UDP-
MurNAC pentapeptide was determined upon THCz treatment of S. aureus to assess if early, 
cytoplasmic steps of peptidoglycan synthesis were inhibited. Furthermore, the response of the 
LiaRS two-component system, which is sensitive to lipid II and C55-PP targeting antibiotics 
(287), was recorded with a luciferase reporter B. subtilis strain. Antagonization of THCz with 
cell envelope precursors was performed in an adapted MIC assay with Micrococcus luteus. 
Furthermore, THCz inhibition of PBP2 mediated peptidoglycan transglycosylation and YbjG 
mediated C55-PP dephosphorylation were examined in in vitro with purified enzymes and 
substrates. Determination of capsular polysaccharide amount of THCz-1 tolerant pneumococci 
was performed in a dot blot assay with an antibody raised against type 4 capsule which was 
purified for additional surface expressed antigens through incubation with the unencapsulated 
isogenic T4R strain.  
4.3 LYSIS BUFFER EVALUATION AND MICROFLUIDIC SETUP 
Lysis buffer evaluation 
Combinations of agents described in the literature were explored for the selective lysis of blood 
cells with the aim to not harm bacterial cells. Blood cell lysis was aspired to be as complete as 
possible in order to reduce the presence of large intact blood cells or debris, that would interfere 
with subsequent size-based label free particle sorting. For the purpose of lysis protocol 
characterization, a flow cytometry protocol was developed, that allowed the size estimation of 
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the lysis debris. Bacterial viability of S. pneumoniae, S. aureus and E. coli in lysed blood was 
compared to their viability in whole blood.  
Gradient acoustic focusing (GAF) 
Acoustic focusing was previously limited to a critical particle diameter of about 2 µm, as for 
particles of a lower diameter acoustic streaming dominated the acoustic radiation force, making 
it impossible to manipulate particles below the critical size. GAF utilizes the stabilizing forces 
of an implemented acoustic impedance gradient to suppress acoustic streaming (288, 289). The 
acoustic impedance of a fluid is characterized by its density and speed of sound. Subjecting 
fluids differing in those characteristics in the center and side inlet of the microfluidic device 
(Figure 4B) creates the acoustic impedance gradient along the channel width. The laminar flow 
pattern (Figure 3B) ensures that the fluids remain in the center and side channels throughout 
the device and can be collected in the respective outlets (Figure 4B). Particle containing 
samples are injected through the side inlets of the chip (Figure 4B). In GAF, the center buffer 
is of higher acoustic impedance than the sample buffer. Upon application of an acoustic 
standing wave, particles move to the pressure node in the center of the microfluidic channel. 
With suppressed acoustic streaming in GAF, particles below the critical diameter can now be 
manipulated with the acoustic standing wave and focused to the microfluidic channel center, 
allowing the subsequent collection in the center outlet.  
4.4 ETHICAL CONSIDERATIONS 
The papers included in the thesis did not rely on animal experiments. For method setup and 
evaluation in paper III, small, anonymized blood samples from healthy volunteers were used. 








5 RESULTS & DISCUSSION 
5.1 HIT DISCOVERY – PHENOTYPIC SCREEN 
17 500 chemicals from the Chemical Biology Consortium Sweden (CBCS) primary screening 
set collection (290), comprising hit like molecules of a wide chemical space, were screened on 
cultures of the unencapsulated T4R strain and it´s parental T4 wildtype strain. 156 chemicals 
(0.9 %) induced lysis in T4R whereof only 71 (0.4 %) induced lysis in the encapsulated T4 
strain. Higher sensitivity of unencapsulated pneumococci could result from reduced negative 
surface charge in absence of the capsule. This might allow access of more negatively charged 
molecules to the cell surface, which could otherwise be repelled in the encapsulated wildtype 
strain. Effect of bacterial surface charge on sensitivity towards antibacterial factors is reported 
for cationic antimicrobial peptides, however with opposite effect (123). The negatively charged 
capsule attracts more cationic peptides, shields modifications on teichoic acids (D-alanylation 
that increases the positive surface charge, Figure 6B) (123) and when shed from the cell surface 
acts as a decoy of antimicrobial peptides (291). The 71 screening hits were clustered by 
chemical properties and two chemical classes thereof were investigated in the thesis: the 
alkylated di-cyclohexyl carboxylic acid (2CCA-1) in paper I and the 1-amino substituted 




 Paper I 
The bactericidal fatty acid mimetic 2CCA-1 selectively targets pneumococcal 
extracellular polyunsaturated fatty acid metabolism 
2CCA-1 is an alkylated di-cyclohexyl carboxylic acid and posseses the typical amphiphatic 
properties of a fatty acid, with a hydrophilic carboxylic acid moiety and a hydrophobic 
extension. The structural difference to the twelve carbon lauric acid are however two 
cyclohexyl residues in the hydrophobic core. Structure activity relationship investigation 
showed that the carboxylic acid moiety as well as the cyclohexyl rings and an aliphatic chain 
of maximal five carbons were indispensable for the potent bactericidal action on S. 
pneumoniae. The suspected decoy for amphiphatic structures is the bacterial cell membrane, 
as it is shown for antibacterial free fatty acids (292, 293). They excert their bactericidal activity 
in a pleiotropic manner by interfearing with membrane physiology and disrubt membrane 
associated processes (292, 293). Even though antibacterial free fatty acids find recognition in 
topical applications such as the curation of skin infections, their potential for use as therapeutics 
is currently limited (292). This is on the one hand due to the eukaryotic cell toxicity of free 
fatty acids (292) and on the other hand because binding to carrier proteins opposes their 
antibacterial function in vivo. However, an innovative delivery strategy with liposome carried 
linoleic acid was shown to be efficiaous in treating Heliobacter pylori gastrointestinal 
infections after oral administration in a mouse model without epithelial cell toxicity (294).  
 
A notable difference to the bactericidal action of free fatty acids, was the potency of 2CCA-1. 
Already approximately 30 times lower concentrations than those of free unsaturated and 
polyunsaturated fatty acids induced cell wall hydrolase mediated lysis. When compared to the 
lysis inducing capacity of the unsaturated twelve carbon chain lauric acid or the saturated 
eighteen carbon chain stearic acid, 2CCA-1 was even around 167 times more potent. Moreover, 
2CCA-1 did not induce premature autolysis in non-growing cultures in stationary phase, even 
at 16 fold the MlytC concentration. This would have been indicative for a membrane associated 
interaction that is independent of the bacterial metabolism, as we observed for polyunsaturated 
fatty acids, nisin or daptomycin. In contrary, 2CCA-1 seems to need actively growing cells to 
excert its function. A clear correlation between growth and activity has long been established 
for the cell wall synthesis inhibitor penicillin (295). 
 
2CCA-1 also induces cell wall hydrolase mediated lysis in S. pneumoniae, a typical response 
to cell wall synthesis inhibiting antibiotics (251, 252). Daptomycin inhibits cell wall synthesis 
by binding and sequestering lipid II, but also interferes with membrane physiology (149, 150). 
Treatment of S. pneumoniae with daptomycin induces cell wall hydrolase mediated lysis 
(Figure 8). The influence of membrane fluidity on cell wall synthesis at high growth rates was 
described for B. subtilis (147). Albeit evoked through an undesired, unspecific membrane 
interaction, detergents also induce LytA mediated lysis (189, 252). Autolysis activation does 





Figure 8 Daptomycin induces cell wall hydrolase mediated lysis. (A) T4 wildtype grown in supplemented C+Y medium 
with added Ca2+ (50 µg/mL). (B) T4ΔlytA a major cell wall hydrolase gene replacement mutant grown in the same medium as 
Tigr4 which additionally contained an elevated concentration of choline chloride (110 mM). Both strains were treated with 
daptomycin (8 µg / mL, 8 x MIC) after reaching stationary phase. The arrows indicate the timepoint of treatment addition. 
Average and standard deviations of triplicate treatments from a representative experiment are shown. 
An important step in target identification and mechanism of action discovery was the analysis 
of 2CCA-1 resistant mutants. Whole genome sequencing revealed that 2CCA-1 resistance 
required inactivation of either the extracellular polyunsaturated fatty acid binding protein 
FakB3 (159), or the transcriptional regulator of the endogenous fatty acid synthesis machinery 
FabT (154). 2CCA-1 resistance of the fakB3 spontaneous and gene replacement mutant 
suggests that uptake of 2CCA-1 was required for the compund to excert activity. An additional 
observation indicating that 2CCA-1 was not excerting antipneumococcal activity through 
unspecific membrane interaction, but rather required active metabolization to show activity.  
 
Gram positive bacteria do not use extracellular fatty acids as energy source through catabolic 
β-oxidation but utilize them as membrane building blocks instead (156, 167, 296). Indeed, 
metabolomic analysis revealed the presence of unique molecular masses in the 2CCA-1 treated 
wildtype pneumococcus, which could be modeled as 2CCA-1 containing lysophosphatidic and 
phosphatidic acid respectively. Those species were not found in the untreated wildtype, nor in 
the 2CCA-1 treated spontaneous resistant fakB3 mutant strain BHN852. Combined, the 2CCA-
1 structure as well as activity characteristics, the resistant pattern and the unique molecular lipid 
species suggest that the compound is metabolized to a toxic phospholipid species.  
 
2CCA-1 induced a dose-dependend change in membrane fluidity upon 2CCA-1 treatment, 
which could be attributable to the short hydrophobic tail of 2CCA-1 containing lipids, and the 
cyclohexyl rings which demand an untypical amount of space directly beneath the lipid head 
group. This constitutes a notable difference to typical cis-unsaturated fatty acids in the 
pneumococcal membrane, which are 16 to 18 carbons long with a double bond ealiest a the 7th 
carbon atom, but more abudant between the 9th and 10th or 11th and 12th carbon atom (134, 154, 
157). Due to the indistuingishability of laurdan generalized polarization between the membrane 
fluidizer benzyl alcohol from the DMSO solvent control, the explanatory power of our 
experiments as to if 2CCA-1 incorporation results in membrane fluidization or rigidification, 
was limited. However, when compared to published experiments, the measured increase in 
laurdan generalized polarization points to a decrease of membrane fluidity after 2CCA-1 
treatment (150, 219). Membrane rigidification was also observed in B. subtilis after daptomycin 
 
32 
treatment, caused by lipid clustering after insertion of the bulky lipopeptide in RIFs (150). 
Similarly, the natural product rhodomyrtone attracted fluid lipids to the site of insertion 
resulting in an increased rigidity of the residual membrane (219). One could hypothesize, that 
2CCA-1 containing lipids are localized in RIFs, as those are rich in lipids with short, branched 
and unsaturated fatty acids (144, 150). Similarly as for daptomycin (150), fluid lipids could be 
attracted to 2CCA-1 lipids to compensate for membrane distortions caused by the spaceous 
dicyclohexyl group adjacent to the lipid head group, resulting in abberant fluid lipid distribution 
and overal membrane rigidification. Complementary experiments are needed to describe 
2CCA-1 induced changes in the pneumococcal membrane and the nature of cell envelope 
synthesis inhibition that results in cell wall hydrolase mediated lysis.  
 
Expression analysis of resistant mutants revealed, that extracellular polyunsaturated fatty acid 
incorporation and endogenous fatty acid synthesis are interdependendly regulated in response 
to extracellular fatty acid availability. The conditions under which we isolated the 2CCA-1 
resistant fabT mutant strain likely represent those of low extracellular polyunsaturated fatty 
acid concentration, during which fakB3 expression was lower when compared to the wildtype 
strain. Loss of FabT under those conditions, could lead to a decreased uptake of 2CCA-1 and 
therefore increased pneumococcal tolerance to the compound. Correspondingly, the fakB3 
mutant tolerated higher concentrations of 2CCA-1 than the fabT mutant, which indicated the 
residual expression of some FakB3 protein for 2CCA-1 uptake in the fabT mutant. Low fatty 
acid concentrations established in the expression studies were a 0.1 mM equimolar mixture of 
saturated, unsaturated and polyunsaturated 18 carbon chain fatty acids. Those could resemble 
the free fatty acid concentrations in the nasal fluid, reported to be in the range of 0.03 - 0.2 mM 
(47). In contrary, fatty acid concentrations of 1 mM established in the expression analysis, 
could resemble the serum concentration of the 18 carbon fatty acid of different sturation degree, 
which was measured to be on average around 5 mM in citizens of the fishing area in the 
japanese town Kumihama (297). We found that FabT repressed fakB3 expression under those 
conditions of high extracellular fatty acid availability, which could ensure membrane 
homeostasis by limiting the phospholipid polyunsaturated fatty acid content.  
 
The expression analysis performed in paper I is limited to the FakB3 homologue of the 
extracellular fatty acid binding proteins, as it was the 2CCA-1 target. Extension of the 
extracellular fatty acid metabolism to FakB1 and FakB2, incorporating saturated and 
unsaturated fatty acids respectively (159), can help to draw a more general picture of the 
regulation of extracellular fatty acid supply and membrane homeostasis. Furthermore, it will 
be interesting to identify mediators of the transcriptional regulation, as we found that FabT 
binding to the fakB3 promoter did not occur. FabT must therefore indirectly influence fakB3 
expression. 
 
An interesting observation was the natural 2CCA-1 resistance of S. aureus, which does not 
encode a FakB3 homologous protein. Bioinformatic analysis revealed that FakB3 homologues 
are with one exception absent in species of the Bacillales order, but widespread in members of 
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the Lactobacillales order. The only species within the Bacillales order where FakB3 
homologues were found, were of the Gemella genus, for which a vivid genetic exchange with 
other members of the oral microbiota such as Streptococci has been described (298). This could 
indicate a selective bactericidal activity of 2CCA-1 to S. pneumoniae and related species 
harboring a FakB3 homologue or a FakB homologue with a similar binding pocket (159).  
 
A limitation of 2CCA-1 in the antibacterial treatment perspective is the exceptionally fast 
adaptation of the pneumococcus to the toxic compound. The possibility of recovering resistant 
mutants already as shortly as two hours after compound exposure, indicates that 2CCA-1 exerts 
a strong selective pressure on the pneumococcus. 
 
Paper I characterizes the small fatty acid like compound 2CCA-1 with a new mechanism of 
action, that provides insight in pneumococcal polyunsaturated fatty acid metabolism 
regulation. 2CCA-1 might serve as tool compound to develop narrow spectrum antibiotics as 
well as to gain further insight in pneumococcal metabolism of fatty acids, the essential 




 Paper II 
THCz - A small molecule with antimicrobial activity that blocks cell wall lipid 
intermediates 
Paper II describes analogs of the 1-amino- substituted tetrahydrocarbazole (THCz) class, that 
induced early logarithmic phase autolysis in the high throughput screen. The screening hit 
THCz-1 and selected analogs displayed activity in the low micromolar range against S. 
pneumoniae and other gram-positive bacteria as well as mycobacteria. Gram-negative bacteria 
with an outer membrane more permeable to hydrophobic compounds, such as Neisseria 
gonorrhoeae and M. catarrhalis (299, 300), and an outer membrane hyper-permeable E. coli 
mutant, were also inhibited by THCz analogs. No activity was recorded against Pseudomonas 
aeruginosa or E. coli wildtype strains, suggesting that THCz cannot permeate the intact outer 
membrane.  
Structure activity relationship studies revealed that the central diamino motif was essential for 
activity, however also responsible for the eukaryotic toxicity of THCz analogs. Furthermore, a 
sterically demanding group and a correctly spaced linking carbon chain at the 1-amino 
substituted position of the tetrahydrocarbazole core was required for bactericidal activity. 
Bactericidal activity as well as cytotoxicity could be modulated by substitutions on the central 
1-amino substituted tetrahydrocarbazole scaffold. The investigated THCz molecules were a 
racemic mixture, the enantiomers of selected analogs did however display similar activity.  
THCz analogs induced rapid bactericidal action and cell wall hydrolase mediated lysis in early 
logarithmic phase. Cell wall synthesis inhibition upon THCz treatment was furthermore 
confirmed with the macromolecular synthesis inhibition assay and the induction of membrane 
blebbing and autolysis in B. subtilis characteristic for cell wall synthesis inhibitors. The target 
within cell wall biosynthesis was narrowed down to lipid II and undecaprenyl pyrophosphate 
as THCz induced the LiaRS two-component system. Indeed, the pyrophosphate moiety of the 
undecaprenyl carrier was determined as minimal binding motif of THCz, and we could show 
that THCz bind to lipid I, lipid II, lipid IIIWTA and lipid Icap. THCz therefore inhibit 
peptidoglycan, teichoic acid and capsular biosynthesis and YbjG mediated C55-P recycling. As 
for nisin (223) and teixobactin (224, 225), interaction with the first sugar of the cell envelope 
precursors was beneficial for the binding affinity of THCz-1 in in vitro biochemical assays. 
The positive charge of THCz-1 at neutral pH supports a model for compound - target 
interaction between the pyrophosphate moiety and the diamino group of the THCz molecules.  
Molecules that target undecaprenyl-pyrophosphate carried cell envelope precursors such as 
nisin, or daptomycin also interfere with membrane integrity. We show though, that THCz 
analogs did not form membrane pores such as the lantibiotic nisin. The rapid killing of THCz 
analogs might nonetheless indicate that membrane interaction could contribute to the 
antibacterial activity, as it was described for telavancin (227). For the lipid II targeting 
lipoglycopeptide with membrane interaction, bactericidal action was observed to occur more 
rapidly in comparison to the glycopeptide vancomycin that solely binds to the extracellular part 
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of lipid II (227, 301). Further investigations are needed to explore possible alterations of 
membrane physiology upon THCz treatment. 
As observed for lipid II and pyrophosphate moiety targeting antibiotics (223, 224, 302), 
resistance to THCz-1 did not easily develop. We could not obtain THCz-1 resistant S. aureus 
strains through continuous incubation in sub-inhibitory concentrations of THCz-1. Also, multi-
antibiotic resistant pneumococcal isolates retained wildtype sensitivity to THCz-1 and the 
analog THCz-40. This was also seen for methicillin- resistant and vancomycin- intermediate 
S. aureus strains as well as vancomycin-resistant Enterococcus faecium, suggesting that 
evolved resistance strategies do not confer cross-protection to THCz. 
Interestingly, S. pneumoniae mutants with increased THCz-1 tolerance were obtained after 
THCz-1 exposure on THY plates. Whole genome sequencing of an isolate of increased THCz-
1 tolerance and subsequent characterization of THCz-1 sensitivity of individual gene 
replacement knockouts of genes with point mutations, revealed that a mutation in cps4E / wciI 
conferred the phenotype. Unlike a complete gene replacement mutant in the first 
glycosyltransferase in capsular biosynthesis, or previously described mutations (209), the 
herein obtained mutation in cps4EG394C resulted in a decreased but not abolished capsular 
polysaccharide production. Decreased THCz-1 sensitivity of the unencapsulated T4R strain 
confirmed the role of the capsular polysaccharide in THCz-1 sensitivity, which could be a result 
of increased availability of the bactoprenyl carrier for cell envelope synthesis other than the 
polysaccharide capsule (210). The capsule is one of the major virulence factors of the 
pneumococcus and chemical induced reduction of the capsular polysaccharide amount might 
help the immune system to clear the infections.  
The THCz analogs synthesized for the untargeted structure activity relationship studies in paper 
II also displayed toxicity towards eukaryotic cells, in a similar concentration range as for 
prokaryotic cells. THCz molecules analogous to the one presented in paper II were reported 
to have antifungal activity (303). Gene replacement mutants of the P-type ATPase homologs 
in S. pneumoniae, which have been identified as fungal targets, retained however wildtype 
sensitivity, possibly, due to the low sequence homology of the eukaryotic and prokaryotic 
target. Together with the available information on the THCz binding interface to the eukaryotic 
target (303), this opens the possibility for further targeted compound design. The synthetic 
accessibility of THCz allows for comparably easy modifications of the molecule in comparison 
to complex natural lipid II targeting products, enabling further exploration and tailoring of the 
bactericidal and cytotoxic properties of the compound.  
Combined, paper II presents a small molecule that binds to undecaprenyl coupled cell 




5.2 MICROFLUIDIC DIAGNOSTIC TOOL DEVELOPMENT 
 Paper III 
Gradient acoustic focusing of sub-micron particles for separation of bacteria 
from blood lysate 
Paper III presents a sample preparation method for bacteria containing complex samples, such 
as whole blood.  
First, blood cells were selectively lysed without compromising bacterial viability. The lysis 
step utilized the different susceptibility of eukaryotic and prokaryotic cell envelope structures 
to stress conditions. An example is the cholesterol dependent membrane disruption of saponins, 
protecting the bacterial cholesterol free membrane from the detergent action (304). Detergent 
sclerosants and lipophilic vitamin K (menadione) have been described to favor platelet lysis 
(305, 306) and utilization of moderate concentrations preserved bacterial viability. The 
evolvement of quick stress response mechanisms in bacteria might also favor their survival in 
environments that provoke eukaryotic blood cell lysis. An access of choline chloride in the 
lysis buffer for reduction of autolysis of S. pneumoniae has been shown to benefit isolation of 
viable bacteria from blood samples (307).  
The lysis step in the sample preparation method presented in paper III, was not yet integrated 
in a microfluidic setup, which would be beneficial for contamination prevention. As 
microfluidic solutions therefore have been proposed (308, 309), the integration of a lysis step 
in a microfluidic compartment could possibly be also applied to the herein presented setup. 
Chemical blood cell lysis of the selected buffer 9 for gradient acoustic focusing (GAF), reduced 
the number of large blood cells and platelet sized particles and did not produce more of about 
1 µm sized particles in the bacteria size range per milliliter of lysate compared to whole blood. 
Small sized lysis debris of a size equivalent to 0.5 µm and below however increased about 2-
log in concentration in lysed blood.  
Therefore, GAF was employed as a second step purify the bacteria from small sized lysis debris 
and perform a buffer exchange. In paper III the methodological development of GAF is 
described. The GAF principle was tested on polystyrene particles as well as S. pneumoniae, S. 
aureus and E. coli, bacterial species that frequently cause septic shock (89). 97.0 ± 0.9 % 
(Average ± standard deviation) of S. aureus, 80.0 ± 2.7 % of E. coli and 70.4 ± 4.2 % of S. 
pneumoniae collected in the device outlets were obtained in the center outlet, in comparison to 
98.24 ± 0.66 % of 1 µm and 37.67 ± 3.22 % of 0.5 µm polystyrene particles. The difference in 
focusing yield between bacterial species might be due to their difference in morphology, yet 
uncharacterized compressibility and the size distribution within a population. However, when 
the device is operated with media of matched acoustic impedance (ΔZ=0, homogenous media) 
in the center and side channel, 63.7 ± 9.4 % of 1 µm particles and 59.9 ± 12.0 % of S. aureus 
were obtained in the center outlet. This shows that with GAF small micrometer sized particles 




For validation of the GAF principle, the device particles and bacteria were dissolved in a BSA 
containing aqueous buffer with low viscosity and a high acoustic impedance difference to the 
center medium. Fluids laminated for GAF need to have an acoustic impedance difference ΔZ 
of more than 1 % so that acoustic streaming is sufficiently suppressed. The acoustic impedance 
of the center buffer was therefore adjusted with the hydrophilic polysaccharide Ficoll to 
establish those conditions in respect to the blood lysate. GAF enabled the isolation of 92.19 ± 
1.11 % of S. aureus in the center outlet of the microfluidic device from three times diluted 
lysate, while lysis debris was reduced by about 70 %. Furthermore, bacteria were transferred 
to a different buffer, judged by the low hemoglobin concentration (20 %) in the center outlet. 
This might also reduce the concentration of lysis agents, and antimicrobial compounds of the 
blood sample, presupposed their diffusion coefficients are comparable to the one of 
hemoglobin. Importantly, the application of GAF allowed the solute exchange and 
concentration dilution without an increase in sample volume.  
A rapid antibiotic susceptibility profile is of high importance for the therapeutic success and 
antibiotic stewardship. Standard antibiotic susceptibility testing in clinical microbiology 
laboratories, such as disk diffusion methods on agar plates (310), require augmentation of 
bacteria through several cultivation steps. Faster methods for the targeted identification of 
genotypic resistance markers cannot fully replace the phenotypic antibiotic susceptibility 
determination for clinical treatment decisions (92, 101). The microfluidic setup based on GAF 
of bacteria from a blood lysate presented in paper III, provides a possibility for label free 
sample decomplexation and preparation of viable bacteria. The lysis step comes with an 
additional advantage as to bacteria that were in the process of being phagocytosed might be 
able to escape the toxic environment (98). This could be one reason for the decrease in time 
until the detection (311, 312) and antibiotic susceptibility determination (313) of the sepsis 
etiologic agent with the lysis centrifugation method, that was invented in the 1970s. 
Furthermore, the size-based separation of bacteria from lysed blood rather than the separation 
of larger blood cells from plasma could favor detection sensitivity, as bacteria can adhere to 
blood cells (314-318) and would otherwise be sorted out (319).  
To summarize, the setup for sample decomplexation presented in paper III allows isolation of 
viable bacteria with an unselective, label free method and the potential to be operated in 
continuous flow in a sealed, contamination preventing microfluidic environment. The sample 
contains a reduced amount of blood cells and debris with the aim to facilitate downstream label 
free microfluidic operations. Continuous operation and the potential to multiplex the 
microfluidic channels, opens the possibility to process a higher sample volume to increase 
detection sensitivity. The preservation of bacterial viability might allow a faster microfluidic 
solution for the phenotypic antibiotic susceptibility determination of the sepsis causing 










6 CONCLUSIONS & POINTS OF PERSPECTIVE 
Antibiotic resistance is an emerging threat to public health. Infections with antibiotic resistant 
bacteria pose a challenge to our society and healthcare systems. Multifaceted approaches and 
innovations are needed to face and resolve the public health threat. In the light of the effective 
and targeted use of antibiotics and successful implementation of innovative treatment 
approaches, it is crucial that novel treatment strategies and diagnostics concurrently evolve. 
Paper I and II characterize hits from a screen for bactericidal chemicals and describe their 
mode of action. Interestingly, those hits differ in their activity spectrum. Activity of compound 
2CCA-1 described in paper I depends on the presence of a fatty acid binding protein 
homologous to the pneumococcal FakB3 with a binding affinity for polyunsaturated fatty acids 
(159). The lack of FakB3 homologues in species belonging to the Bacillales order, provides an 
explanation for the tolerance of S. aureus to 2CCA-1. S. pneumoniae, belonging to the 
Lactobacillales order, displays exceptional sensitivity to the compound and incorporates 
2CCA-1 in its membrane phospholipids. The structural features of the compound and measured 
2CCA-1 induced membrane fluidity alterations, suggest the disruption of membrane 
homeostasis as cause of the bactericidal effect.  
While we recorded a rather narrow spectrum for 2CCA-1, the THCz compound class described 
in paper II possesses a comparably broad activity spectrum. THCz analogs were active against 
gram-positive S. pneumoniae, S. pyogenes, S. aureus, B. subtilis, and Enterococcus faecalis to 
name a selection, and to mycobacteria as well as gram-negative N. gonorrhoeae and M. 
catarrhalis in low micromolar concentrations. This is attributed to the conservation of the 
THCz target among prokaryotes. In paper II we identify the THCz target to be undecaprenyl 
pyrophosphate carried cell envelope precursors lipid I, lipid II, lipid IIIWTA and Lipid Icap with 
undecaprenyl pyrophosphate as minimal binding partner. THCz analogs thereby inhibit all 
major branches of cell envelope synthesis with low resistance development propensity.  
The responsible use of antibiotics requires a fast and precise diagnosis. It is even more 
indispensable for the development and use of narrow spectrum antibiotics, which impact the 
microbiota with less collateral damage and might therefore inherently decelerate the rate of 
resistance development. When a novel treatment is to be in place, readily available, affordable 
and precise diagnostics will be crucial to help serving the ethical responsibility of best treatment 
for an individual patient that is only administered if absolutely necessary to serve societies need 
for the preservation of a valuable resource. 
Microfluidic operations provide the possibility to handle fluids on a single bacteria level an 
offer huge potential for innovations that meet the need for fast, precise and comparably cheap 
diagnosis. This is especially true for microfluidic solutions that offer the possibility for a “lab 
on a chip”, which can be employed on the bedside, in households and rural environments.  
The microfluidic approach for sample decomplexation of bacteria containing blood, presented 
in paper III could be a first step of an integrated microfluidic solution for antibiotic 
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susceptibility determination of the sepsis causing pathogen. The setup described in paper III 
approaches the complex sample through the reduction of the excess of blood cells and isolation 
of viable bacteria. This might allow faster identification and susceptibility profile 
characterization with microfluidic downstream operations, providing a shortcut to the time-
consuming cultivation steps for an accelerated diagnosis and targeted treatment of sepsis. 
Future research is needed to inquire if 2CCA-1 is effective as antibacterial agent in vivo and 
can be formulated to improve pharmacological properties. Further medicinal chemistry efforts 
are required to decrease the toxicity of THCz analogs and investigate, if and how THCz interact 
with the bacterial membrane. Microfluidic operations downstream of the setup presented in 
paper III need to be developed or integrated and the setup needs to be validated on clinical 
sepsis specimens. 
In conclusion, the thesis hopes to contribute work that may serve information for the 
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